The role of IL-4 in Heligmosomoides polygyrus-induced alterations in murine intestinal epithelial cell function.
IL-4 and IL-13 promote gastrointestinal worm expulsion, at least in part, through effects on nonlymphoid cells, such as intestinal epithelial cells. The role of IL-4/IL-13 in the regulation of intestinal epithelial function during Heligmosomoides polygyrus (Hp) infection was investigated in BALB/c mice infected with Hp or treated with a long-lasting formulation of recombinant mouse IL-4/alphaIL-4 complexes (IL-4C) for 7 days. Separate groups of BALB/c mice were drug-cured of initial infection and later reinfected and treated with anti-IL-4R mAb, an antagonist of IL-4 and IL-13 receptor binding, or with a control mAb. Segments of jejunum were mounted in Ussing chambers, and short circuit current responses to acetylcholine, histamine, serotonin, PGE2, and glucose were determined. Although only modest changes in epithelial cell function were observed during primary Hp infection, IL-4C or a secondary Hp infection each induced more dramatic changes, including increased mucosal permeability, reduced sodium-linked glucose absorption, and increased Cl- secretory response to PGE2. Some, but not all, effects of IL-4C and Hp infection were dependent on enteric nerves. Hp-induced changes in epithelial function were attenuated or prevented by anti-IL-4R mAb. Thus, IL-4/IL-13 mediate many of the effects of Hp infection on intestinal epithelial cell function and do so both through direct effects on epithelial cells and through indirect, enteric nerve-mediated prosecretory effects. These immune system-independent effector functions of IL-4/IL-13 may be important for host protection against gastrointestinal nematodes.
Shea-Donohue
T
T
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA. tshea@usuhs.mil
Sullivan
C
C
Finkelman
F D
FD
Madden
K B
KB
Morris
S C
SC
Goldhill
J
J
Piñeiro-Carrero
V
V
Urban
J F
JF
D000818:Animals; D019138:Antibodies, Blocking / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015232:Dinoprostone / Q000494:pharmacology; D005260:Female; D006369:Heligmosomatoidea / Q000276:immunology*; D006632:Histamine / Q000494:pharmacology; D018793:Interleukin-13 / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015847:Interleukin-4 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000502:physiology*; D007411:Intestinal Diseases, Parasitic / Q000276:immunology / Q000473:pathology; D007413:Intestinal Mucosa / Q000166:cytology / Q000276:immunology* / Q000294:innervation / Q000469:parasitology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009474:Neurons / Q000276:immunology; D019948:Receptors, Interleukin-4 / Q000276:immunology / Q000502:physiology; D017206:Strongylida Infections / Q000276:immunology / Q000473:pathology
D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D018793:Interleukin-13; D019948:Receptors, Interleukin-4; D015847:Interleukin-4; D006632:Histamine; D015232:Dinoprostone